ABSTRACT
INTRODUCTION: There are a limited number of studies about the clinical findings of coronavirus infection in pediatric patients with asthma. We aimed to evaluate the clinical and laboratory characteristics of pediatric patients with asthma and healthy children without chronic disease who infected with SARS-CoV-2. METHODS: This is a retrospective, case-control study comparing the asthma diagnosed and healthy children who were diagnosed as COVID-19 in our hospital between March 11 and November 10, 2020. RESULTS: During the study period, 6,205 children were diagnosed with CO-VID-19 in our hospital. Only 54 (0.87%) patients had a diagnosis of asthma. The mean of the age was 10.5 years and 53.7% (n:29) of the patients with asthma were male. Cough, shortness of breath, emesis, and diarrhea were found to be significantly higher in asthma group than in the control group (respectively p = 0.002, 0.000, 0.002, 0.019, 0.015). Patients who were given SABA was significantly higher in asthma diagnosed patients (p = 0.000). Hospitalization was significantly higher in asthma group (p = 0.025), and the duration of hospitalization was significantly higher in control group (p = 0.034). There was no significant difference between the 2 groups in terms of requiring oxygen treatment and in laboratory findings between groups. CONCLUSION: This study revealed that pediatric patients diagnosed with asthma were in a mild clinic. According to these findings, asthma may not affect the course of the COVID-19 in children.
Subject(s)
Asthma/epidemiology , COVID-19/epidemiology , SARS-CoV-2 , Adolescent , Adrenergic beta-Agonists/therapeutic use , Anti-Asthmatic Agents/therapeutic use , Asthma/diagnosis , Asthma/therapy , COVID-19/diagnosis , COVID-19/therapy , Child , Cough/diagnosis , Cough/epidemiology , Cough/therapy , Diarrhea/diagnosis , Diarrhea/epidemiology , Diarrhea/therapy , Dyspnea/diagnosis , Dyspnea/epidemiology , Dyspnea/therapy , Female , Hospitalization/statistics & numerical data , Humans , Male , Oxygen Inhalation Therapy , Retrospective Studies , Vomiting/diagnosis , Vomiting/epidemiology , Vomiting/therapySubject(s)
COVID-19 , Delivery of Health Care , Nurse Specialists , Primary Health Care , Self Care , Urinary Incontinence/nursing , Urinary Tract Infections/nursing , Administration, Topical , Adrenergic beta-Agonists/therapeutic use , Anti-Bacterial Agents/therapeutic use , Cholinergic Antagonists/therapeutic use , Estrogens/therapeutic use , Health Services Accessibility , Humans , Incontinence Pads , Life Style , Pelvic Floor , Recurrence , SARS-CoV-2 , Self-Management , State Medicine , United Kingdom , Urinary Bladder, Overactive/drug therapy , Urinary Bladder, Overactive/nursing , Urinary Incontinence, Stress/nursing , Urinary Tract Infections/drug therapyABSTRACT
BACKGROUND: Viral infections are known to exacerbate asthma in adults. Previous studies have found few patients with asthma among severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia cases. However, the relationship between SARS-CoV-2 infection and severe asthma exacerbation is not known. OBJECTIVE: To assess the frequency of asthma exacerbation in patients with asthma hospitalized for SARS-CoV-2 pneumonia and compare symptoms and laboratory and radiological findings in patients with and without asthma with SARS-CoV-2 pneumonia. METHODS: We included 106 patients between March 4 and April 6, 2020, who were hospitalized in the Chest Diseases Department of Strasbourg University Hospital; 23 had asthma. To assess the patients' asthma status, 3 periods were defined: the last month before the onset of COVID-19 symptoms (p1), prehospitalization (p2), and during hospitalization (p3). Severe asthma exacerbations were defined according to Global INitiative for Asthma guidelines during p1 and p2. During p3, we defined severe asthma deterioration as the onset of breathlessness and wheezing requiring systemic corticosteroids and inhaled ß2 agonist. RESULTS: We found no significant difference between patients with and without asthma in terms of severity (length of stay, maximal oxygen flow needed, noninvasive ventilation requirement, and intensive care unit transfer); 52.2% of the patients with asthma had Global INitiative for Asthma step 1 asthma. One patient had a severe exacerbation during p1, 2 patients during p2, and 5 patients were treated with systemic corticosteroids and inhaled ß2 agonist during p3. CONCLUSIONS: Our results demonstrate that patients with asthma appeared not to be at risk for severe SARS-CoV-2 pneumonia. Moreover, SARS-CoV-2 pneumonia did not induce severe asthma exacerbation.